AI assistant
ETHZilla Corp — Director's Dealing 2025
Jun 20, 2025
33039_dirs_2025-06-20_74ef2534-83e1-435d-8b5e-b40ee9a75ef8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: 180 Life Sciences Corp. (ATNF)
CIK: 0001690080
Period of Report: 2025-06-17
Reporting Person: Shoemaker Stephen H (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-17 | Common Stock | A | 72297 | $0.0 | Acquired | 137297 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-17 | Non-Qualified Stock Option (right to buy) | $0.929 | A | 165000 | Acquired | 2035-06-17 | Common Stock (165000) | Direct |
Footnotes
F1: Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/2 of such shares on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2022 Equity Compensation Plan.
F2: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer.
F3: The options vest 1/2 on each of December 17, 2025 and June 17, 2026, subject to the recipient's continued service to the Issuer. Issued under the Issuer's 2025 Option Incentive Plan. The 2025 Option Incentive Plan is subject to stockholder approval and (i) no options can be exercised prior to obtaining stockholder approval for such plan, and (ii) the outstanding options will be cancelled, if stockholder approval is not obtained.